Everolimus Reduces Cancer Risk and Proves Cost-Effective in Liver Transplant

Balancing Long-Term Complications in Liver Transplant Maintenance

Long-term survival after liver transplantation is increasingly dictated by non-graft complications, particularly the development of chronic kidney disease and de novo malignancies. While standard calcineurin inhibitors remain the cornerstone of immunosuppression, their dose-dependent nephrotoxicity frequently leads to significant renal impairment over time [1, 2]. Mammalian target of rapamycin inhibitors, such as everolimus, have emerged as a potential alternative to facilitate calcineurin inhibitor reduction, aiming to preserve glomerular filtration rates and leverage potential anti-neoplastic effects [3, 4]. However, these benefits must be weighed against a distinct profile of adverse events, including impaired wound healing and altered immune responses [5, 6]. A new study now offers insights into the cost-effectiveness and clinical impact of this combination therapy by modeling the complex interplay between cancer prevention, renal preservation, and infection risk.

Quantifying the Trade-off Between Malignancy and Infection

To evaluate the clinical impact of adding everolimus to a standard calcineurin inhibitor regimen, the researchers utilized a Cox regression model, which is a statistical method used to estimate the time until a specific event occurs while accounting for multiple variables. This model allowed for the calculation of adjusted hazard ratios for the risk of cancer and posttransplant infection, providing a clearer picture of how everolimus alters the long-term safety profile for liver transplant recipients. By adjusting for potential confounders, the study sought to isolate the specific effect of the mammalian target of rapamycin inhibitor on these two critical, yet opposing, clinical outcomes. The findings demonstrated a substantial protective effect against de novo malignancies, which remain a leading cause of late mortality in transplant patients. The addition of everolimus significantly reduced the risk of cancer with a hazard ratio of 0.435 (95% confidence interval, 0.279 to 0.678). This reduction suggests that the anti-proliferative properties of everolimus may counteract some of the oncogenic risks associated with long-term calcineurin inhibitor use. For clinicians, this represents a potential strategy for managing patients at high risk for malignancy, provided the medication is initiated as part of a combination strategy rather than as monotherapy. However, this oncological benefit is tempered by a heightened susceptibility to pathogens. The study found that the addition of everolimus increased the infection risk in subsequent years with a hazard ratio of 1.468 (95% confidence interval, 1.053 to 2.045). This nearly 47 percent increase in infection risk highlights the necessity of vigilant monitoring and potentially more aggressive prophylactic measures when intensifying immunosuppression with everolimus. Clinicians must therefore balance the clear reduction in cancer risk against this elevated probability of infectious complications when tailoring maintenance therapy for liver transplant recipients.

Economic Modeling of Co-occurring Complications

Post-liver transplant complications, specifically cancer, infections, and renal dysfunction, impose a substantial clinical and economic impact on recipients. To address these burdens, the researchers conducted a cohort analysis and a cost-utility analysis to evaluate the clinical impacts and cost-effectiveness of adding everolimus to a calcineurin inhibitor-based regimen. The study specifically aimed to identify how the co-occurrence of these major complications shifts the overall cost-effectiveness of the treatment strategy, comparing recipients who received calcineurin inhibitors with everolimus to those who received calcineurin inhibitor monotherapy. To simulate long-term outcomes, the researchers utilized a Markov model, which is a mathematical framework used to simulate the progression of chronic diseases by modeling transitions between different health states over time. This model captured the complex co-occurrence of liver disease, infection, and renal dysfunction over time. The researchers applied this model to a hypothetical cohort of 10,000 liver transplant recipients aged 55 years, simulating their clinical course over a 30-year period. By tracking these transitions, the model estimated total costs and quality-adjusted life years, which is a metric that combines both the quantity and quality of life lived. These data were then used to calculate the incremental cost-effectiveness ratio (ICER), a measure of the additional cost required to gain one year of healthy life when comparing two different treatment strategies.

Renal Preservation Drives Value Despite Infection Costs

The cost-utility analysis revealed that the strategy of combining a calcineurin inhibitor with everolimus is economically favorable, yielding an incremental cost-effectiveness ratio of US$5298 per quality-adjusted life year. This figure represents the additional cost required to achieve one year of life in perfect health and is well below the established willingness-to-pay threshold of $25,000 per quality-adjusted life year. For clinicians, this suggests that the clinical benefits of adding everolimus, particularly in reducing malignancy, are achieved at a cost that is highly sustainable within standard healthcare budgets. The economic value of the regimen fluctuates significantly depending on which post-transplant complications are considered in the model. When the analysis was limited to liver disease alone, the incremental cost-effectiveness ratio was $9307 per quality-adjusted life year. However, the inclusion of renal dysfunction as a co-occurring complication markedly improved the value proposition, causing the ratio to decrease to $4363 per quality-adjusted life year. This shift highlights the significant economic benefit of the renal-sparing effects associated with everolimus use, as preserving kidney function avoids the high costs of dialysis or secondary transplantation. Conversely, when the costs and quality-of-life impacts of post-transplant infection were added to the analysis, the ratio increased to $10,464 per quality-adjusted life year, reflecting the higher clinical burden and resource utilization associated with infectious episodes. Despite these fluctuations, the calcineurin inhibitor with everolimus regimen remained cost-effective across all co-occurring outcomes and perspectives modeled in the study. The findings indicate that the reduction in cancer risk and the preservation of renal function sufficiently offset the increased costs and morbidity associated with a higher infection rate. This robust economic profile supports the use of everolimus as a viable strategy for balancing the complex, long-term risks of malignancy, infection, and renal failure in liver transplant recipients.

References

1. Bzeizi KI, Smith R, Albenmousa A, et al. Long-Term Outcomes of Everolimus Therapy in De Novo Liver Transplantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. Transplantation proceedings. 2021. doi:10.1016/j.transproceed.2020.09.021

2. Miyata H, Morita Y, Kumar A. A Systematic Review of the Literature on Chronic Kidney Disease Following Liver Transplantation.. Annals of transplantation. 2022. doi:10.12659/AOT.935170

3. Kumar A, Ahmad M, Hussain A, et al. Efficacy and safety of everolimus with reduced tacrolimus versus standard tacrolimus in liver transplant recipients: A systematic review and meta-analysis of randomized controlled trials.. Transplant immunology. 2025. doi:10.1016/j.trim.2025.102317

4. Yan X, Huang S, Yang Y, et al. Sirolimus or Everolimus Improves Survival After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2022. doi:10.1002/lt.26387

5. Zhang G, Duan B, Li G. mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: A systematic review and meta-analysis.. Clinical transplantation. 2022. doi:10.1111/ctr.14823

6. Lin M, Mittal S, Sahebjam F, Rana A, Sood GK. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.. Clinical transplantation. 2017. doi:10.1111/ctr.12872